Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer

Modern Pathology

Volumn 26, Issue 1, 2013, Pages 79-86

  Yamamoto Ibusuki, Mutsuko ^a   Yamamoto, Yutaka ^a   Yamamoto, Satoko ^a   Fujiwara, Saori ^a   Fu, Peifen ^a,b   Honda, Yumi ^a   Iyama, Ken Ichi ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; gene expression; risk score

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOW RISK POPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84871924686     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.151     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecularportraits of human breast tumours. Nature 2000;406:747-752
2. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Geneexpression profiling predicts clinical outcome of breastcancer. Nature 2002;415:530-536 (Pubitemid 34130608)
3. Carey LA, Perou CM, Livasy CA, et al. Race, breastcancer subtypes, and survival in the Carolina BreastCancer Study. JAMA 2006;295:2492-2502 (Pubitemid 43854964)
4. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds fortherapies: highlights of the St Gallen InternationalExpert Consensus on the primary therapy of earlybreast cancer 2009. Ann Oncol 2009; 20:1319-1329
5. Goldhirsch A, Wood WC, Coates AS, et al. Strategiesfor subtypes-dealing with the diversity of breastcancer: highlights of the St Gallen International ExpertConsensus on the primary therapy of early breastcancer 2011. Ann Oncol 2011;22:1736-1747
6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2status, and prognosis of patients with luminal B breastcancer. J Natl Cancer Inst 2009;101:736-750
7. Cuzick J, Dowsett M, Pineda S, et al. Prognostic valueof a combined estrogen receptor, progesterone receptor,Ki-67, and human epidermal growth factor receptor 2immunohistochemical score and comparison with theGenomic Health recurrence score in early breastcancer. J Clin Oncol 2011;29:4273-4278
8. Paik S, Shak S, Tang G, et al. A multigene assay topredict recurrence of tamoxifen-treated, node-negativebreast cancer. N Engl J Med 2004;351:2817-2826 (Pubitemid 40051905)
9. Harris L, Fritsche H, Mennel R, et al. American Societyof Clinical Oncology 2007 update of recommendationsfor the use of tumor markers in breast cancer. J ClinOncol 2007;25:5287-5312 (Pubitemid 350232263)
10. Engstrom PF, Bloom MG, Demetri GD, et al. NCCNmolecular testing white paper: effectiveness, efficiency,and reimbursement. J Natl Compr Canc Netw2011;9(Suppl 6):S1-S16
11. Dabbs DJ, Klein ME, Mohsin SK, et al. High falsenegativerate of HER2 quantitative reverse transcriptionpolymerase chain reaction of the Oncotype DXtest: an independent quality assurance study. J ClinOncol 2011;29:4279-4285
12. Badve SS, Baehner FL, Gray RP, et al. Estrogen-andprogesterone-receptor status in ECOG 2197: comparisonof immunohistochemistry by local and centrallaboratories and quantitative reverse transcriptionpolymerase chain reaction by central laboratory. J ClinOncol 2008;26:2473-2481
13. Baehner FL, Achacoso N, Maddala T, et al. Humanepidermal growth factor receptor 2 assessment in acase-control study: comparison of fluorescence in situhybridization and quantitative reverse transcriptionpolymerase chain reaction performed by centrallaboratories. J Clin Oncol 2010;28:4300-4306
14. Ibusuki M, Fu P, Yamamoto S, et al. Establishment of astandardized gene-expression analysis system usingformalin-fixed, paraffin-embedded, breast cancerspecimens. Breast Cancer 2011 (e-pub ahead of print)
15. McShane LM, Altman DG, Sauerbrei W, et al. REportingrecommendations for tumor MARKer prognosticstudies (REMARK). Nat Clin Pract Urol 2005;2:416-422 (Pubitemid 43115010)
16. Iwase H, Yamamoto Y, Kawasoe T, et al. Advantage ofsentinel lymph node biopsy before neoadjuvantchemotherapy in breast cancer treatment. Surg Today2009;39:374-380
17. Goldhirsch A, Glick JH, Gelber RD, et al. Meetinghighlights: International Consensus Panel on thetreatment of primary breast cancer. Seventh InternationalConference on Adjuvant Therapy of PrimaryBreast Cancer. J Clin Oncol 2001;19:3817-3827 (Pubitemid 32880060)
18. Goldhirsch A, Wood WC, Gelber RD, et al. Meetinghighlights: updated international expert consensus onthe primary therapy of early breast cancer. J Clin Oncol2003;21:3357-3365 (Pubitemid 46606270)
19. Goldhirsch A, Glick JH, Gelber RD, et al. Meetinghighlights: international expert consensus on theprimary therapy of early breast cancer 2005. AnnOncol 200516:1569-1583 (Pubitemid 41511089)
20. Goldhirsch A, Wood WC, Gelber RD, et al. Progressand promise: highlights of the international expertconsensus on the primary therapy of early breastcancer 2007. Ann Oncol 2007;18:1133-1144 (Pubitemid 47244357)
21. Fu P, Ibusuki M, Yamamoto Y, et al. Quantitativedetermination of insulin-like growth factor 1 receptormRNA in formalin-fixed paraffin-embedded tissues ofinvasive breast cancer. Breast Cancer 2011 (e-pubahead of print)
22. Yamamoto S IM, Yamamoto Y, Fu P, et al. Clinicalrelevance of Ki67 gene expression analysis using formalinfixedand embedded in paraffin (FFPE) breast cancerspecimens. Breast Cancer 2012 (e-pub ahead of print)
23. Barberis M, Pellegrini C, Cannone M, et al. QuantitativePCR and HER2 testing in breast cancer: a technicaland cost-effectiveness analysis. Am J Clin Pathol2008;129:563-570 (Pubitemid 352029275)
24. Hammond ME, Hayes DF, Dowsett M, et al. AmericanSociety of Clinical Oncology/College Of AmericanPathologists guideline recommendations for immunohistochemicaltesting of estrogen and progesteronereceptors in breast cancer. J Clin Oncol 2010;28:2784-2795
25. Middleton LP, Price KM, Puig P, et al. Implementationof American Society of Clinical Oncology/College ofAmerican Pathologists HER2 Guideline Recommendationsin a tertiary care facility increases HER2 immunohistochemistryand fluorescence in situ hybridizationconcordance and decreases the number of inconclusivecases. Arch Pathol Lab Med 2009;133:775-780
26. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment ofKi67 in breast cancer: recommendations from theInternational Ki67 in Breast Cancer working group.J Natl Cancer Inst 2011;103:1656-1664